Skip to main content

Table 2 The clinical manifestations of disease in each study group

From: A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients

Clinical symptoms and signs

Treatment group

Number (%)

Control group

Number (%)

Blurred vision

3 (10)

8 (32)

Diplopia

6 (20)

4 (16)

Gait problem

4 (13.3)

2 (8)

Paresthesia

8 (26.6)

6 (24)

Muscle weakness

3 (10)

3 (12)

Dysarthria

0 (0)

6 (24)

Bladder dysfunction

1 (3.3)

1 (4)